Advances in treatment of systemic sclerosis.docVIP

 PAGE \* MERGEFORMAT 15 Advances in treatment of systemic sclerosis [Keywords:] systemic sclerosis; treatment progress Systemic sclerosis (systemic sclerosis, SSc) is a joint ?p involving the skin, gastrointestinal tract, lung, kidney and heart of the connective tissue disease. Sara Simeoni [1] first reported such a combination in patients with lesions in the nervous system. At present tend to believe that excessive oxidative stress causes early SSc endothelial dysfunction appears to promote fibroblast proliferation. I make the following progress in their treatment reviewed. 1 drugs 1.1 Antioxidant treatment of vascular endothelial dysfunction can occur early in SSc, almost 90% of patients with Raynaud’s phenomenon as initial symptoms illustrate this point. Therefore, once widely used vasoactive agents in early treatment of SSc. However, in recent years many The results show that all causes reactive oxygen species (ROS) and increased oxidative stress caused by the existence of the wide range of SSc skin fibrosis ?p ?p organs and immune abnormalities of vascular injury is closely related to lipid peroxidation, and early in the disease than advanced disease may occur as a causative link in SSc, it is antioxidant therapy may be the most effective treatment for early disease [2]. now has a clear effect of the antioxidant drugs such as nifedipine ?p probucol. past that nifedipine as a vasodilator has a certain effect on Raynaud’s phenomenon, but recent research shows that the inhibition of mononuclear cells can produce O2 , SSc patients to reduce markers of oxidation of blood circulation, and thus from the treatment of SSc, nifedipine at 30 ~ 60mg / d The dose range can significantly reduce the severity of Raynaud’s phenomenon [3]. Prostaglandin derivatives, probucol can inhibit monocyte adhesion and reduce the susceptibility of LDL oxidation, reducing endothelial cell damage, and the improvement of Raynaud’s phenomenon than nifedipine [4]. Other a